BIOADVANCED SILICONE
中文 Ask BIO AI
Industry Insights

Industry Insights · Regulatory · Registration · Quality

China's 'AI+Manufacturing' plan names BCI and surgical robots

At the national level, 'AI+Manufacturing' is now a special action — naming BCI, surgical robots and intelligent diagnosis directly, giving medical-device intelligence a clear policy lever.

2026-01-12BIO Industry Insights

Diagram of the AI+Manufacturing policy across the device chain: smart terminals, BCI, surgical robots, diagnostics
The policy spans the chain from upstream smart chips to downstream surgical robots and diagnostic systems, naming BCI a priority new terminal. Illustrative.
In short: On 8 Jan 2026, eight ministries — MIIT, the Cyberspace Administration, NDRC, Education, Commerce, SASAC, SAMR and the National Data Administration — jointly issued the 'AI+Manufacturing' Special Action. It calls for accelerating smart-terminal upgrades (on-device models, toolchains); focusing on industrial inspection and telemedicine; accelerating industrialization of AR/VR wearables and BCI; advancing upstream smart chips (high-end training chips, on-device inference chips); and accelerating downstream surgical robots and intelligent diagnostic systems in smart medical equipment.

Which medical directions it names

  • BCI: a new smart terminal, accelerate industrialization and commercialization;
  • Surgical robots, intelligent diagnostics: accelerate innovation and clinical adoption of smart medical equipment;
  • Upstream chips: high-end training chips, on-device inference chips, high-speed interconnect.

The industry read

BCI is at the inflection from 'breakthrough → clinical validation → commercialization', globally split into 'US-led invasive, China-leading non-invasive', with competition on electrodes, chips, algorithms. Near-term commercialization is non-invasive; the long-term core is the (semi-)invasive 'flexible electrode + high-throughput low-power chip', multi-center trials and standards.

The BIO angle

The BCIs and surgical robots the policy names all depend, in hardware, on materials in body contact or implantation: flexible-electrode insulation, device encapsulation and device seals all need medical-grade silicone/polymers. BIO supplies these 'AI+device' programs with upstream materials and selection support.

FAQ

Who issued the policy and when?

On 8 Jan 2026, eight ministries led by MIIT jointly issued the 'AI+Manufacturing' Special Action.

How does it relate to medical devices?

It explicitly accelerates BCI, AR/VR wearables, surgical robots and intelligent diagnostics, and pushes upstream smart-chip breakthroughs.

What does it mean for upstream materials?

Electrode insulation, encapsulation and seals in BCI and surgical robots need reliable medical silicone/polymers — materials are a foundation for 'AI+device' deployment.

Related reading

Browse all insights →

Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.

Building in China's medical-device market?

From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.

Contact BIO Silicone sourcing guide
Contact BIO